Clinical trials: Myeloma Multiple
Multiple Myeloma, Myeloma
Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma
Myeloma is the second most common type of blood cancer in the United States. Myeloma most commonly affects older adults. While some younger individuals do get myeloma, the average age when people are first diagnosed with myeloma…
- Conditions
- Multiple Myeloma, Myeloma, Disability Physical, Disabilities Multiple
- Trial name
- NCT04999085
- Testing
- Supportive care interventions
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Multiple Myeloma, Primary Amyloidosis
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
The goal of this clinical research study is to learn whether higher doses of stem cells can help to decrease the symptoms that occur after melphalan.
- Trial name
- NCT00651937
- Testing
- Melphalan, Stem Cell Infusion, Questionnaires
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
This is a Phase 2 open-label study to evaluate the efficacy and safety of ibrutinib in combination with bortezomib and dexamethasone for patients with relapsed or relapsed and refractory multiple myeloma.
- Trial name
- NCT02902965
- Testing
- Ibrutinib, Bortezomib, Dexamethasone
- Where
- 33 sites in Czechia, Germany and 4 more
- Volunteers
- 74 people
- Sponsor
- Pharmacyclics Switzerland GmbH
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
- Trial name
- NCT00963872
- Testing
- cyclophosphamide, fludarabine phosphate, Total body irradiation
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with feladilimab (GSK3359609), and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore…
- Trial name
- NCT07217119
- Testing
- Belantamab mafodotin, Feladilimab
- Where
- 11 sites in United States, Australia and 6 more
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
This study will be available to any participant who has received or is currently receiving belantamab mafodotin treatment through either a clinical trial, an access program, or a physician prescription.
- Trial name
- NCT04549363
- Testing
- Belantamab mafodotin
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
Study of the efficacy and safety of bortezomib administered in combination with vorinostat in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT00773747
- Testing
- Vorinostat, bortezomib
- Volunteers
- 637 people
- Sponsor
- Merck Sharp & Dohme LLC
Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
The main objectives are to evaluate the safety and tolerability of AMG 176 monotherapy in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia.
- Trial name
- NCT02675452
- Testing
- AMG 176, Azacitidine, Itraconazole
- Where
- 24 sites in United States, Australia and 3 more
- Volunteers
- 141 people
- Sponsor
- Amgen
Chronic Myeloproliferative Disorders, Leukemia
T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Malignant Plasma Cell Neoplasms
- Trial name
- NCT00589602
- Testing
- peripheral blood lymphocyte therapy, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- The Cleveland Clinic
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
This phase I trial studies the side effects and best dose of BCMA CAR-T cells in treating patients with BCMA positive multiple myeloma that has come back or does not respond to treatment.
- Trial name
- NCT03338972
- Testing
- Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma
The purpose of this study is to evaluate the safety and effect on the body of Tabalumab (LY2127399) in combination with bortezomib and dexamethasone in Japanese participants with relapsed or refractory multiple myeloma (MM).
- Trial name
- NCT01556438
- Testing
- Tabalumab, Bortezomib IV, Bortezomib SC
- Where
- 5 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Eli Lilly and Company
Multiple Myeloma
Selinexor Treatment of Refractory Myeloma
This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd) dosed twice weekly in four-week cycles, in patients with penta-refractory MM (Parts 1 and 2) or quad refractory MM…
- Trial name
- STORM (NCT02336815)
- Testing
- Selinexor, Dexamethasone
- Where
- 61 sites in United States, Austria and 4 more
- Volunteers
- 202 people
- Sponsor
- Karyopharm Therapeutics Inc
Plasma Cell Myeloma
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients
The purpose of this study it to compare the efficacity of isatuximab when combined to carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with multiple myeloma already treated with 1 to 3 prior lines of…
- Trial name
- IKEMA (NCT03275285)
- Testing
- isatuximab SAR650984, carfilzomib, dexamethasone
- Where
- 70 sites in United States, Australia and 14 more
- Volunteers
- 302 people
- Sponsor
- Sanofi
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia
- Trial name
- NCT00589563
- Testing
- anti-thymocyte globulin, cyclophosphamide, etoposide
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma
This is a phase II, multicenter, open label, nonrandomized study to evaluate the efficacy and safety of lenalidomide at a dose of 10 mg/dose in combination with bortezomib at 1.0 mg/m2/dose, pegylated liposomal doxorubicin (PLD)…
- Trial name
- NCT01160484
- Testing
- DVD-R
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma
A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
This is a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the combination regimen of daratumumab plus durvalumab (D2).
- Trial name
- FUSION-MM-005 (NCT03000452)
- Testing
- DARATUMUMAB, DURVALUMAB
- Where
- 25 sites in United States, Austria and 4 more
- Volunteers
- 18 people
- Sponsor
- Celgene
Multiple Myeloma
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
This study was a multi-center, open-label, single-arm, Phase 2 study where newly diagnosed Multiple Myeloma requiring systemic chemotherapy will be eligible for enrollment. A total of 46 subjects were enrolled.
- Trial name
- NCT02969837
- Testing
- Elotuzumab, Carfilzomib, Lenalidomide
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- University of Chicago
Multiple Myeloma
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
This is a research study to see if a new drug called bortezomib is useful to treat multiple myeloma in people who are newly diagnosed, and have not yet received treatment for their disease.
- Trial name
- NCT01090921
- Testing
- Bortezomib
- Where
- 11 sites in United States
- Volunteers
- 50 people
- Sponsor
- Boston VA Research Institute, Inc.
Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
The purpose of this study is to determine if peripheral blood cells collected following AMD3100 mobilization can be used safely for hematopoietic cell transplantation into HLA-matched recipients.
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Lymphocytic Leukemia, Chronic
- Trial name
- NCT00241358
- Testing
- AMD3100, Stem Cell Transplant
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Washington University School of Medicine
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
This randomized clinical trial studies standard GVHD prophylaxis with tacrolimus and methotrexate compared to tacrolimus, mycophenolate mofetil and a reduced-dose methotrexate in patients with hematologic malignancies undergoing…
- Conditions
- Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia
- Trial name
- NCT01951885
- Testing
- tacrolimus, methotrexate, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Case Comprehensive Cancer Center